{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Showing 1 - 3 of 3 results
Status:
Investigational
Source:
NCT01466088: Phase 2 Interventional Completed Alzheimer's Disease
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
ISPRONICLINE is a partial agonist at the a4b2 subtype of nicotinic acetylcholine receptors (nAChRs) without interaction with other nAChRs or other receptor systems. It has antidepressant, nootropic, and neuroprotective effects. It progressed to phase II clinical trials for the treatment of dementia and Alzheimer's disease but is no longer under development.
Status:
Investigational
Source:
NCT01466088: Phase 2 Interventional Completed Alzheimer's Disease
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
ISPRONICLINE is a partial agonist at the a4b2 subtype of nicotinic acetylcholine receptors (nAChRs) without interaction with other nAChRs or other receptor systems. It has antidepressant, nootropic, and neuroprotective effects. It progressed to phase II clinical trials for the treatment of dementia and Alzheimer's disease but is no longer under development.
Status:
Investigational
Source:
NCT01466088: Phase 2 Interventional Completed Alzheimer's Disease
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
ISPRONICLINE is a partial agonist at the a4b2 subtype of nicotinic acetylcholine receptors (nAChRs) without interaction with other nAChRs or other receptor systems. It has antidepressant, nootropic, and neuroprotective effects. It progressed to phase II clinical trials for the treatment of dementia and Alzheimer's disease but is no longer under development.
